Pifithrin-α supresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis

被引:151
作者
Zhang, M
Liu, W
Ding, D
Salvi, R
机构
[1] SUNY Buffalo, Ctr Hearing & Deafness, Hearing Res Lab, Buffalo, NY 14214 USA
[2] Roswell Pk Canc Inst, Dept Mol Pharmacol, Buffalo, NY 14263 USA
关键词
hair cells; caspase-1; caspase-3; utricle; cochlea; protection;
D O I
10.1016/S0306-4522(03)00286-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cisplatin, a commonly used antineoplastic agent, destroys the sensory hair cells in the cochlear and vestibular system leading to irreversible hearing loss and balance problems. Cisplatin-induced hair cell damage presumably occurs by apoptosis. Recent studies suggest that p53 may play an important role initiating cisplatin-induced apoptosis in some cell types. To determine if p53 plays a role in cisplatin-mediated hair cell loss, cochlear and utricular organotypic cultures were prepared from postnatal day 3-4 rats and treated with cisplatin or cisplatin plus pifithrin-alpha (PFT), a p53 inhibitor. Control cultures were devoid of p53 immunolabeling, caspase-1 and caspase-3 labeling and p53 protein was absent from Western blots. Cisplatin (1-10 mug/ml) caused a dose-dependent loss of hair cells in cochlear and utricular cultures, up-regulated phospho-p53 serine 15 immunolabeling, increased the expression of phospho-p53 serine 15 in Western blots from 6 to 48 h after the onset of cisplatin-treatment, and increased caspase-1 and caspase-3 labeling in cochlear and vestibular cultures. Addition of PFT (20100 muM) to cisplatin-treated cochlear and utricular cultures resulted in a dose-dependent increase in hair cell survival; suppressed the expression of p53 in Western blots and eliminated caspase-1 and caspase-3 labeling in cultures. These results suggest that the tumor suppressor protein, p53, plays a critical role in initiating apoptosis in cochlear and vestibular hair cells. Temporary suppression of p53 with PFT provides significant protection against cisplatin-induced hair cell loss and offers the potential for reducing the ototoxic, vestibulotoxic and neurotoxic side effects of cisplatin. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:191 / 205
页数:15
相关论文
共 84 条
[1]   Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea [J].
Alam, SA ;
Ikeda, K ;
Oshima, T ;
Suzuki, M ;
Kawase, T ;
Kikuchi, T ;
Takasaka, T .
HEARING RESEARCH, 2000, 141 (1-2) :28-38
[2]   Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors [J].
Amstad, PA ;
Yu, G ;
Johnson, GL ;
Lee, BW ;
Dhawan, S ;
Phelps, DJ .
BIOTECHNIQUES, 2001, 31 (03) :608-+
[3]   CISPLATIN - EVALUATION OF ITS OTOTOXIC POTENTIAL [J].
ANNIKO, M ;
SOBIN, A .
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1986, 7 (04) :276-293
[4]   ACTIVATION OF INTERLEUKIN-1-BETA BY A CO-INDUCED PROTEASE [J].
BLACK, RA ;
KRONHEIM, SR ;
SLEATH, PR .
FEBS LETTERS, 1989, 247 (02) :386-390
[5]   CISPLATIN-INDUCED OTOTOXICITY - AUDIOMETRIC FINDINGS AND EXPERIMENTAL COCHLEAR PATHOLOGY [J].
BOHEIM, K ;
BICHLER, E .
ARCHIVES OF OTO-RHINO-LARYNGOLOGY-ARCHIV FUR OHREN-NASEN-UND KEHLKOPFHEILKUNDE, 1985, 242 (01) :1-6
[6]  
Clarke DM, 1999, MOL UROL, V3, P25
[7]   Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants [J].
Clerici, WJ ;
Hensley, K ;
DiMartino, DL ;
Butterfield, DA .
HEARING RESEARCH, 1996, 98 (1-2) :116-124
[8]   EARLY MORPHOLOGICAL AND CHEMICAL-CHANGES INDUCED BY CISPLATIN IN THE GUINEA-PIG ORGAN OF CORTI [J].
COMIS, SD ;
RHYSEVANS, PH ;
OSBORNE, MP ;
PICKLES, JO ;
JEFFRIES, DJR ;
PEARSE, HAC .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1986, 100 (12) :1375-1383
[9]   A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β-peptide [J].
Culmsee, C ;
Zhu, XX ;
Yu, QS ;
Chan, SL ;
Camandola, S ;
Guo, ZH ;
Greig, NH ;
Mattson, MP .
JOURNAL OF NEUROCHEMISTRY, 2001, 77 (01) :220-228
[10]   Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and -independent pathways [J].
Cummings, BS ;
Schnellmann, RG .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :8-17